Inventor
ANDREZ JEAN-CHRISTOPHE
CA14 patents
⚠️ This page may combine multiple inventors who share the name “ANDREZ JEAN-CHRISTOPHE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GENENTECH INC
7 patentsUS8952169B2Feb 10, 2015
N-substituted benzamides and methods of use thereof
GENENTECH INC25 citations92
US10005724B2Jun 26, 2018
Therapeutic compounds and methods of use thereof
GENENTECH INC6 citations83
US9694002B2Jul 4, 2017
Substituted benzamides and methods of use thereof
GENENTECH INC11 citations83
US9546164B2Jan 17, 2017
Substituted benzamides and methods of use thereof
GENENTECH INC13 citations83
US10526285B2Jan 7, 2020
Therapeutic compounds and methods of use thereof
GENENTECH INC1 citations72
US10125098B2Nov 13, 2018
Therapeutic compounds and methods of use thereof
GENENTECH INC2 citations72
US11149002B2Oct 19, 2021
Therapeutic compounds and methods of use thereof
GENENTECH INC0 citations61
XENON PHARMACEUTICALS INC
7 patentsUS10246453B2Apr 2, 2019
Benzenesulfonamide compounds and their use as therapeutic agents
XENON PHARMACEUTICALS INC10 citations82
US11299490B2Apr 12, 2022
Benzenesulfonamide compounds and their use as therapeutic agents
XENON PHARMACEUTICALS INC3 citations71
US11174268B2Nov 16, 2021
Benzenesulfonamide compouds and their use as therapeutic agents
XENON PHARMACEUTICALS INC2 citations71
US10662184B2May 26, 2020
Benzenesulfonamide compounds and their use as therapeutic agents
XENON PHARMACEUTICALS INC4 citations71
US11639351B2May 2, 2023
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
XENON PHARMACEUTICALS INC0 citations61
US10981905B2Apr 20, 2021
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
XENON PHARMACEUTICALS INC1 citations61
US10752623B2Aug 25, 2020
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
XENON PHARMACEUTICALS INC1 citations60